摘要
目的:探讨双丹明目胶囊联合羟苯磺酸钙治疗糖尿病视网膜病变(diabetic retinopathy,DR)的疗效及对血清血管内皮生长因子(VEGF)、血小板源性生长因子(PDGF)及白细胞介素1(IL-1)水平的影响。方法:将2016年12月至2018年12月武安市第一人民医院收治的120例DR患者按照随机数字表法分为对照组和研究组,每组60例。对照组患者采用羟苯磺酸钙治疗,研究组患者在对照组基础上加用双丹明目胶囊治疗,均连续治疗4个月。比较两组患者的临床疗效,治疗前后证候评分、中文版低视力者生活质量量表(Chinese-version low vision quality of life questionnaire,CLVQOL)评分、黄斑厚度、出血斑面积及血清VEGF、PDGF和IL-1水平;观察不良反应发生情况。结果:研究组的总有效率为95.00%(57/60),明显高于对照组的83.33%(50/60),差异有统计学意义(P=0.040)。治疗后,两组患者的证候评分均较治疗前明显降低,CLVQOL评分均明显升高,且研究组患者上述评分改善程度明显优于对照组,差异均有统计学意义(P<0.05);两组患者黄斑厚度、出血斑面积均较治疗前明显减小,且研究组患者上述指标改善程度明显优于对照组,差异均有统计学意义(P<0.05);两组患者血清VEGF、PDGF及IL-1水平均较治疗前明显降低,且研究组患者上述指标水平明显低于对照组,差异均有统计学意义(P<0.05)。治疗期间,两组患者均无严重不良反应发生。结论:双丹明目胶囊联合羟苯磺酸钙治疗DR的疗效显著,能够明显改善临床症状,提高患者生活质量,降低血清VEGF、PDGF及IL-1水平,且安全性较好。
OBJECTIVE: To investigate the clinical efficacy of Shuangdan Mingmu capsules combined with calcium dobesilate in the treatment of diabetic retinopathy(DR) and its effects on serum levels of vascular endothelial growth factor(VEGF), platelet-derived growth factor(PDGF) and interleukin-1(IL-1). METHODS: Totally 120 patients with DR admitted into Wu’an the First People’s Hospital from Dec. 2016 to Dec. 2018 were extracted to be divided into the control group and the study group via the random number table, with 60 cases in each group. Patients in the control group were treated with calcium dobesilate, while the study group were treated with Shuangdan Mingmu capsules on the basis of the control group, and both groups were treated for 4 months. Clinical efficacy, syndrome score, Chinese-version low vision quality of life questionnaire(CLVQOL) score, macular thickness, area of hemorrhage and serum VEGF, PDGF and IL-1 levels before and after treatment of two groups were compared, and the adverse drug reactions were recorded. RESULTS: The total effective rate of the study group was 95.00%(57/60), significantly higher than that of the control group 83.33%(50/60), and the difference was statistically significant(P=0.040). After treatment, the syndrome scores of two groups were significantly lower compared with those before treatment, and the CLVQOL scores were significantly higher;the improvement degree of the above-mentioned scores in the study group was significantly better than that in the control group, with statistically significant differences(P<0.05). The macula thickness and the area of hemorrhage in both groups were significantly reduced compared with those before treatment, and the improvement degree of the above indexes in the study group was significantly better than that in the control group, with statistically significant differences(P<0.05). The serum levels of VEGF, PDGF and IL-1 in both groups were significantly lower than those before treatment, and the levels of the above indexes in the study group was significantly lower than those in the control group, the difference was statistically significant(P<0.05). During treatment, no severe adverse drug reactions occurred in either group. CONCLUSIONS: The efficacy of Shuangdan Mingmu capsules combined with calcium dobesilate in the treatment of DR is significant, which can significantly improve the clinical symptoms and patients’ quality of life, and reduce the serum VEGF, PDGF and IL-1 levels, with higher safety.
作者
柳洁平
孔玉红
王玲
LIU Jieping;KONG Yuhong;WANG Ling(Dept.of Ophthalmology,Wu’an the First People’s Hospital,Hebei Wu’an 056300,China)
出处
《中国医院用药评价与分析》
2019年第11期1332-1334,1338,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
河北省2019年度医学科学研究课题计划项目(No.20191645)
